Latest news

• Dupixent dulls pain of diabetes slump at Sanofi

  New rheumatoid arthritis therapy Kevzara (sarilumab), an IL-6 inhibitor predicted to become a $1bn-plus product despite entering a fairly crowded market, was approved in the US in May and

• NICE backs Sanofi's Kevzara for routine NHS use

  NICE backs Sanofi's Kevzara for routine NHS use. Recommends the RA treatment in combination with methotrexate. ... Sanofi is celebrating a positive recommendation from the UK’s cost effectiveness watchdog for its rheumatoid arthritis (RA) treatment

• FDA wants more data on J&J’s arthritis drug Plivensia

  An IL-6 inhibitor, Plivensia would compete with other drugs in the class, namely Roche’s well-established Actemra (tocilizumab) and Sanofi/Regeneron’s new entrant Kevzara (sarilumab), which claimed its ... Actemra made sales of $1.7bn last year, but

• Setback for J&J as FDA panel turns down arthritis drug sirukumab

  s Kevzara (sarilumab), which was approved in the US in May at the second attempt. ... Unlike Actemra and Kevzara, which target the IL-6 receptor, J&J's drug targets the IL-6 molecule itself.

• Solid start for Dupixent as Sanofi raises 2017 outlook

  Sanofi also has high expectations for just-approved rheumatoid arthritis therapy Kevzara (sarilumab), an IL-6 inhibitor predicted to become a $1bn-plus product despite entering a fairly crowded market.